Retrobulbar injection of amphotericin B using intravenous cannula for post-COVID-19 rhino-orbital mucormycosis.
Indian J Ophthalmol
; 70(1): 302-305, 2022 Jan.
Article
in English
| MEDLINE | ID: covidwho-1596279
ABSTRACT
Rhino-orbital mucormycosis has seen a huge resurgence in patients post COVID-19 infection. In patients with minimal orbital disease and especially with preserved vision, retrobulbar injections of amphotericin B can be of great help in controlling the disease. Instead of giving daily injections of amphotericin B using needles every time, we used an 18-gauge intravenous (IV) cannula with injection port and suture holes to deliver the amphotericin into the orbital space for a period of 5 days. Patients were more compliant and less distressed with this method compared with being given an injection with a needle daily. We got a good response in terms of orbital disease regression with this method. In our review of the literature, we did not come across any such case of amphotericin B injection using an IV cannula. Injection of amphotericin B into the orbit using an IV cannula is a viable and easy treatment option for cases of rhino-orbital mucormycosis.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Orbital Diseases
/
Eye Infections, Fungal
/
COVID-19
/
Mucormycosis
Type of study:
Case report
/
Diagnostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Indian J Ophthalmol
Year:
2022
Document Type:
Article
Affiliation country:
Ijo.IJO_1511_21
Similar
MEDLINE
...
LILACS
LIS